Adrianne Funmaker, APRN
Psychiatric/Mental Health · Little Rock, ARNPI 1063965192
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.8%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Corium, LLC at 52.4% of the total. Reporting peaked in 2023 at $3,448 and has fallen 78.7% since, to $733 in 2024. Among psychiatric/mental health clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 151 payments — averaging $31.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$3K
- Otsuka America Pharmaceutical, Inc.$399
- AbbVie$384
- Alkermes, Inc.$296
- Axsome Therapeutics, Inc.$245
- Teva Pharmaceuticals USA, Inc.$244
- plus $722 from 9 others
What the payments were for
- Consulting fees$3457%
- Speaking & faculty fees$1,61033%
- Travel & lodging$271%
- Food & beverage$2,82559%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corium, LLC | 26 | $2,517 |
| Otsuka America Pharmaceutical, Inc. | 18 | $399 |
| AbbVie | 37 | $384 |
| Alkermes, Inc. | 10 | $296 |
| Axsome Therapeutics, Inc. | 12 | $245 |
| Teva Pharmaceuticals USA, Inc. | 10 | $244 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $201 |
| Johnson & Johnson | 6 | $144 |
| Lundbeck LLC | 7 | $130 |
| Neurocrine Biosciences, Inc. | 6 | $110 |
| Vanda Pharmaceuticals Inc. | 3 | $49 |
| Idorsia Pharmaceuticals US Inc | 2 | $34 |
| Almatica Pharma LLC | 1 | $22 |
| Noven Therapeutics, LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Azstarys$1,955
How this compares
$4,807 in reported general payments places this provider in the 90th percentile of 359 psychiatric/mental health providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vilazodone Hcl | 26 | $3,109 |
| Buspirone Hcl | 11 | $105 |
| Guanfacine Hcl | 11 | $101 |
| Clonazepam | 13 | $78 |
| Lamotrigine | 13 | $70 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Little Rock
- Cara MeckfesselLittle Rock$8K
- Stacey HughesLittle Rock$7K
- Michelle HeadLittle Rock$6K
- Sara JonesLittle Rock$6K
- Alicia BarosLittle Rock$6K
- Chloe WardLittle Rock$4K
- Ashley TaylorLittle Rock$4K
- Kizzie HoustonLittle Rock$3K
- Jennifer RawlsLittle Rock$3K
- Stephanie BohannonFayetteville$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.